Poland· PL-100083052
Depulol
A medicinal product containing rosmarini aetheroleum + eucalypti aetheroleum + balsamum peruvianum, registered in Poland by Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Rosmarini aetheroleum + Eucalypti aetheroleum + Balsamum peruvianum
- Manufacturer
- Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990789115
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4dd5777c-54cd-4f1f-af37-0fe1e55a1811 GET /v1/drugs/4dd5777c-54cd-4f1f-af37-0fe1e55a1811?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Żel",
"source": "urpl",
"strength": "(5 g + 5 g + 6 g)/100 g",
"packaging": "05909990789115 ¦ OTC ¦ 12503\n1 op. 20 g",
"substance": "Rosmarini aetheroleum 5 g/100 g + Eucalypti aetheroleum 5 g/100 g + Balsamum peruvianum 6 g/100 g",
"common_name": "Rosmarini aetheroleum + Eucalypti aetheroleum + Balsamum peruvianum",
"pl_product_id": "100083052",
"pozwolenie_nr": "07891",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about rosmarini aetheroleum + eucalypti aetheroleum + balsamum peruvianum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.